Acute Effects of BCAA and L-Arginine on Performance in Elite Soccer Players
NCT ID: NCT07347509
Last Updated: 2026-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2025-01-10
2025-09-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Twenty-one football players participating in the T.F.F. U-19 Development League will be randomly assigned to one of three groups: BCAA (n = 7), L-arginine (n = 7), or placebo (n = 7). Participants will receive either 12 g of BCAA (4:1:1), 5 g of L-arginine, or an equivalent amount of maltodextrin, administered 1.5 hours before training.
Performance assessments will include 10 m and 20 m sprint tests, an agility test, the Wingate anaerobic power test, blood lactate measurements, and post-exercise heart rate recovery measurements taken at the 1st, 3rd, and 5th minutes of recovery.
Data will be analyzed using repeated measures analysis of variance to examine within- and between-group differences.Data obtained from the study were analyzed using the JASP 0.95.4 software. Pre-test and post-test values of the experimental and control groups were evaluated using Repeated Measures ANOVA. Effect size was determined using Eta Squared (η²), and differences between groups were identified using Tukey post hoc analysis. A 95% confidence interval was applied, and statistical significance was accepted at p \< 0.05.
In the BCAA group, 20 m sprint performance (p \< 0.05) and agility test results (p \< 0.05) improved significantly compared to the control group. Additionally, heart rate recovery at the 3rd and 5th minutes was significantly faster in the BCAA group compared to both the L-arginine and placebo groups (p \< 0.05). In the L-arginine group, no significant improvements were observed in sprint performance, agility, lactate response, or Wingate parameters compared to placebo. No significant differences were found between groups in lactate response or anaerobic power variables (peak, mean, and minimum power, and fatigue index) (p \> 0.05).
A single dose of BCAA supplementation improves short-distance sprint performance, agility, and heart rate recovery in football players; however, it does not have a significant effect on anaerobic power or lactate response. Acute L-arginine supplementation did not produce a significant ergogenic effect on these parameters. The findings suggest that amino acid supplementation may produce more pronounced effects with chronic rather than acute application
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of L-arginine Supplementation on Anaerobic Exercise Performance
NCT06475391
Effects of L-Arginine and Citrulline Malate Supplementation on Sport Performance in Physically Active Men
NCT06938126
β-Alanine for Kickboxing Anaerobic Performance
NCT07319052
The Effect of Acute Beetroot Juice Supplementation on Anaerobic Performance in Football Players
NCT07048912
EFFECTS OF L-ARGININE SUPPLEMENTATION ON THE RECOVERY OF CARDIORESPIRATORY PARAMETERS AFTER SUBMAXIMAL EXERCISE TEST
NCT06405477
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A total of 21 male football players competing in the Turkish Football Federation (T.F.F.) U-19 Development League will be recruited for the study. Participants will be randomly allocated into three groups: BCAA supplementation group (n = 7), L-arginine supplementation group (n = 7), and placebo group (n = 7). Randomization will be performed using a computer-generated random allocation sequence. Both participants and investigators will be blinded to group assignments throughout the study.
Participants in the BCAA group will receive a single oral dose of 12 g BCAA in a 4:1:1 ratio, while the L-arginine group will receive 5 g of L-arginine. The placebo group will receive an equivalent amount of maltodextrin. All supplements will be administered 1.5 hours prior to the training session under standardized conditions.
Following supplementation, participants will complete a standardized warm-up protocol before undergoing performance assessments. Performance measures will include 10 m and 20 m sprint tests to assess sprint speed, an agility test to evaluate change-of-direction ability, and the Wingate anaerobic power test to assess anaerobic performance parameters. Blood lactate concentrations will be measured at specified time points, and heart rate recovery will be recorded at the 1st, 3rd, and 5th minutes following exercise.
All testing procedures will be conducted under similar environmental and training conditions to minimize external variability. Data collected from the assessments will be used to examine acute physiological and performance responses to the supplementation protocols using appropriate statistical methods.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BCAA Supplementation Group
Participants received a single acute oral dose of branched-chain amino acids (BCAA) prior to the anaerobic performance, speed, agility, and recovery tests.
BCAA
A single acute oral dose of branched-chain amino acids (BCAA) administered prior to the anaerobic performance, speed, agility, and recovery tests.
L-Arginine Supplementation Group
Participants received a single acute oral dose of L-arginine prior to the anaerobic performance, speed, agility, and recovery tests.
L-Arginine
A single acute oral dose of L-arginine administered prior to testing.
MIX Supplementation Group
Participants received a placebo supplement prior to the anaerobic performance, speed, agility, and recovery tests.
bcaa and l arginine
A placebo supplement administered prior to testing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BCAA
A single acute oral dose of branched-chain amino acids (BCAA) administered prior to the anaerobic performance, speed, agility, and recovery tests.
L-Arginine
A single acute oral dose of L-arginine administered prior to testing.
bcaa and l arginine
A placebo supplement administered prior to testing.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Actively competing in a youth development or amateur football league
Minimum of 3 years of regular football training experience
Training at least 4 days per week
Free from musculoskeletal injury in the last 6 months
No use of nutritional supplements (including BCAA or L-arginine) for at least 4 weeks prior to the study
Voluntary participation with written informed consent
Exclusion Criteria
Use of medications or supplements that may affect performance outcomes
History of surgery within the last 6 months
Known allergy or intolerance to BCAA or L-arginine
Smoking or alcohol abuse
Failure to comply with study protocol
19 Years
19 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ataturk University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Gökhan Atasever
Associate Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Atatürk University
Erzurum, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ID SBA-2025-15316
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
CST-SOCCER-2024
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.